A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Sponsor: Jazz Pharmaceuticals
Where it's recruiting
Phoenix · Tucson
Cerritos · Glendale · Los Angeles · San Francisco
Aurora · Denver
Washington D.C.
Fort Myers · Jacksonville · St. Petersburg · West Palm Beach
Boston
Coon Rapids · Rochester
Kansas City
Hackensack · New Brunswick
Long Island City · New York
Asheville · Durham · Morrisville
Cincinnati · Cleveland
Source: ClinicalTrials.gov · NCT06435429 · last updated 2026-02-10